Selonabant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication.[1][2][3] It was also previously being developed to treat obesity, but development for this indication was discontinued.[1] The drug is administered by intravenous infusion.[1] It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial.[3] Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals.[1][2] As of December 2024, it is in phase 2 trials.[1][2]

See also

References

  1. ^ a b c d e "Anebulo Pharmaceuticals". AdisInsight. 26 December 2024. Retrieved 25 February 2025.
  2. ^ a b c "Delving into the Latest Updates on Selonabant with Synapse". Synapse. 23 January 2025. Retrieved 25 February 2025.
  3. ^ a b Gorbenko AA, Heuberger JA, Juachon M, Klaassen E, Tagen M, Lawler JF, et al. (February 2025). "CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial". Clinical Pharmacology and Therapeutics. doi:10.1002/cpt.3581. PMID 39898464.
Allikas: https://en.wikipedia.org/wiki/Selonabant
No tags for this post.